Adult Dosing
Treatment of HIV Infection
- Recommended dose: 400 mg PO tid
- Use in combination with other antiretroviral therapy
Notes:- Prior to consumption, disperse 100 mg tablets in water and stir until a uniform dispersion occurs; take the 200 mg tablets as intact tablets as they are not readily dispersed in water
- Patients receiving both delavirdine and antacids should be advised to take them at least 1 hr apart
- Patients with achlorhydria should take delavirdine with an acidic beverage such as orange or cranberry juice
Pediatric Dosing
- Safety and effectiveness in pediatric patients <16 yrs have not been established
Treatment of HIV Infection (Children >16 yrs)
- Recommended dose: 400 mg PO tid
- Use in combination with other antiretroviral therapy
Notes:- Prior to consumption, disperse 100 mg tablets in water and stir until a uniform dispersion occurs; take the 200 mg tablets as intact tablets as they are not readily dispersed in water
- Patients receiving both delavirdine and antacids should be advised to take them at least 1 hr apart
- Patients with achlorhydria should take delavirdine with an acidic beverage such as orange or cranberry juice
[Outline]
See Supplemental Patient Information
- Prior to initiating therapy, inquire about medicines that should not be taken concomitantly with delavirdine. Serious and/or fatal drug interactions could result from inappropriate co-administration of certain drugs, as delavirdine may inhibit the metabolism of many different drugs
- Concomitant use of lovastatin/simvastatin is not recommended. Exercise caution if co-administered with other HMG-CoA reductase inhibitors because co-administration may increase the risk of myopathy including rhabdomyolysis
- Caution should be exercised if used concurrently with sildenafil as it may substantially increase sildenafil concentrations, which may result in an increase in sildenafil-associated adverse events such as hypotension, visual changes, and priapism
- Co-administration of St.John's wort or St.John's wort containing products is not recommended
- As delavirdine is metabolized primarily in the liver, caution should be exercised when administering to patients with impaired hepatic function
- During the initial phase of combination antiretroviral therapy, patients whose immune system respond may develop an inflammatory response to residual opportunistic infections requiring further evaluation and treatment
- Autoimmune disorders including Graves disease, polymyositis, and Guillain-Barré syndrome may occur in the setting of immune reconstitution
- Therapy when used alone or in combination may confer cross-resistance to other non-nucleoside reverse transcriptase inhibitors
- Suspend therapy immediately if severe rash, including erythema multiforme and Stevens-Johnson syndrome, occurs
- Body fat redistribution or accumulation leading to central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been reported in patients receiving antiretroviral therapy
Caution: Use cautiously in
Supplemental Patient Information
- Emphasize patients to find out about medicines that should be avoided with delavirdine
- Inform patients that delavirdine is not a cure for HIV-1 infection and they may continue to experience illnesses associated with HIV infection such as opportunistic infections. Advise patients to seek medical help for any significant health changes
- Instruct patients to discontinue therapy and promptly contact their physician if they experience severe rash or rash accompanied by symptoms such as fever, oral lesions, conjunctivitis, swelling, and muscle joint aches
- Advise HIV-infected mothers not to breastfeed their infants due to the risk of HIV transmission
Pregnancy Category:C
Breastfeeding: Unsafe; women with HIV infection should not breastfeed their infants. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 25 January 2011).The Centers for Disease Control and Prevention recommend that HIV-infected mothers should not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection. As per manufacturer's data, HIV-infected mothers should be instructed not to breastfeed their infants during delavirdine therapy.
Pricing data from www.DrugStore.com in U.S.A.
- Rescriptor 200 MG TABS [Bottle] (VIIV HEALTHCARE)
30 mg = $59.99
90 mg = $170.98
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Rescriptor 100 MG Oral Tablet
Ingredient(s): Delavirdine
Imprint: U;3761
Color(s): White
Shape: Oval
Size (mm): 19.00
Score: 1
Inactive Ingredient(s): lactose / microcrystalline cellulose / croscarmellose sodium / magnesium stearate / colloidal silicon dioxide / carnauba wax / opadry white ys-1-7000-e
Drug Label Author:
Pharmacia and Upjohn Company
DEA Schedule:
Non-Scheduled
Drug Name: Rescriptor 200 MG Oral Tablet
Ingredient(s): Delavirdine
Imprint: RESCRIPTOR;200;mg
Color(s): White
Shape: Oval
Size (mm): 17.00
Score: 1
Inactive Ingredient(s): lactose / microcrystalline cellulose / croscarmellose sodium / magnesium stearate / colloidal silicon dioxide / carnauba wax / hypromellose / opadry white ys-1-18202-a / pharmaceutical ink black
Drug Label Author:
Pharmacia and Upjohn Company
DEA Schedule:
Non-Scheduled
